Back

Positioning Imatinib for Pulmonary Arterial Hypertension (PIPAH) study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Current pharmacological treatments for pulmonary hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Alexander Rothman

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Effects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL).
Doctor M. Waligora (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension
Doctor M. Stracqualursi (Milan, IT)
Abstract Slides Video
Presentation thumbnail
The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials
Mr H. Khasawneh (Irbid, JO)
Abstract Slides Video
Presentation thumbnail
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
Doctor H. Tokgoz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Metoprolol therapy in patients with Eisenmenger syndrome (MINES) study. A single-centre, double-blinded, randomised, placebo-controlled trial
Doctor A. Pius (New Delhi, IN)
Abstract Slides Video

Access the full session

Session thumbnail
Current pharmacological treatments for pulmonary hypertension

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Angel and devil: the game-changing drug for chronic myeloid leukaemia
thumbnail
Congress Presentation
Adults with congenital heart disease and pulmonary arterial hypertension: Quantitative assessment of haemodynamic parameters under disease targeting therapy - A retrospective multicentre analysis
thumbnail
Congress Presentation
Prognostic value of follow-up hemodynamics after initial treatment in pulmonary arterial hypertension

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources